You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
健康元(600380.SH):今年已陸續引進流感藥物TG-1000等多個新藥
格隆匯 07-27 08:43

格隆匯7月27日丨健康元(600380.SH)近期在接待機構投資者調研時表示,妥布黴素吸入溶液如果今年能順利進入醫保目錄,明年形成規模化銷售,從患病率、患病人數來測算,還是具有一定的市場。公司馬來酸茚達特羅吸入粉霧劑於2022年下半年已申報生產,如該產品能夠成功獲批,可能成為公司第一個獲批的粉霧劑產品,標誌着公司在粉霧劑領域的重大突破。沙美特羅替卡松吸入粉霧劑原研品種的已過專利保護期很長時間,迄今中國沒有一個仿製藥上市,公司該產品的審評進度仍處於第一梯隊,未來也屬於比較有潛力的產品。

除自主研發外,公司持續關注前沿技術,不斷加強外部合作,通過授權引進、合作開發等多種方式,積極尋求公司優勢領域產品,今年公司已陸續引進流感藥物TG-1000、治療肺水腫藥物JRF-106等多個新藥,拓展呼吸系統其他疾病,鞏固公司呼吸賽道優勢地位,後續公司也將完善核心產品梯隊建設,進而實現長期可持續發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account